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Abstract The first EGF-like module of human coagulation
factor IX contains a single functionally important calcium ion
binding site. We have now shown the dissociation constant for
this site to be approximately 160 WM in a recombinant protein
fragment consisting of residues 1^85 in human fIX. This
represents a W10-fold increase in affinity as compared with
the isolated EGF module (residues 46^85). The Gla module (here
with Glu instead of Gla) thus increases the affinity of the EGF
module calcium ion binding site. Each of two mutations, V46E
and Q50E, made to investigate whether the extra negative charge
would increase the affinity of the calcium binding site manifested
a negligible increase in affinity.
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1. Introduction
Coagulation factor IX (fIX) is a single-chain molecule with
415 amino acid residues. It is the precursor of the serine pro-
tease, factor IXa (fIXa), that activates factor X (fX) to fXa in
the blood coagulation cascade [1,2]. Factors IX and X are
homologues, as are their cofactors, factors VIIIa and Va.
Limited proteolysis of fIX in two steps results in the forma-
tion of the physiologically active form of fIX, fIXaL. Factor
IX can be activated either by factor XIa, or by factor VIIa in
complex with its membrane-bound cofactor, tissue factor. Ac-
tivation of fX takes place with fIXaL bound to its cofactor,
factor VIIIa, forming a membrane-bound macromolecular
complex.
Factor IX is a vitamin K-dependent protein with an N-
terminal Q-carboxyglutamic acid (Gla) containing module
which is followed by two modules that are homologous to
the epidermal growth factor (EGF) precursor. The C-terminal
part of fIXa harbors the catalytic serine protease module. The
structure of porcine factor IXa has been determined by X-ray
crystallography [3]. However, the protein-protein and protein-
phospholipid interactions that are required for assembly of
the macromolecular complex are still poorly understood. In
contrast to the factor VIIa-tissue factor complex, the factor
IXa-factor VIIIa complex has not yet been crystallized and
studied by X-ray crystallography [4]. It has, however, been
amply demonstrated that occurrence of the conformational
changes that follow fIX and fX activation is a prerequisite
for their high a⁄nity interaction with their respective cofac-
tors. Moreover, three types of calcium binding sites are im-
portant for complex assembly and biological activity. The Gla
module binds V10 Ca2 required for the interaction between
fIXa and biological membranes, and the ¢rst EGF-like mod-
ule binds one Ca2 which appears to be required to secure an
orientation between the Gla and the ¢rst EGF-like module
that is compatible with biological activity [5,6]. Finally, there
is a single Ca2 binding site in the serine protease module.
The importance of these Ca2 binding sites has been demon-
strated by analysis of naturally occurring mutants causing
hemophilia B, and by site-directed mutagenesis studies [7^9].
The Ca2 a⁄nity of the isolated EGF module is low both in
fIX (human; KdW1.8 mM) [8] and in fX (bovine; KdW1
mM) [10]. In fX the Ca2 a⁄nity increases approximately
20-fold when the EGF module is linked to the Gla module
[11]. This increase does not require the Glu residues to be
carboxylated to Gla. The structures of the N-terminal EGF-
like modules of fIX and fX have been studied both by NMR
spectroscopy (fIX and X) and by X-ray di¡raction (fIX) [12^
14]. X-ray crystallography determination of the structure of
the synthetic N-terminal EGF module from fIX has enabled
six ligands for the calcium ion to be identi¢ed: Asp-47, Gly-
48, Gln-50, Asp-64 (bidentate interaction) and Asp-65 where
residues 47, 50 and 64 provide side-chain ligands and residues
48 and 65 provide ligands from their backbone carbonyl
groups [13]. This is in complete agreement with results previ-
ously obtained with NMR spectroscopy of the calcium-bound
EGF module from factor X [14].
In this study, we wanted to investigate whether the Gla
module has the same e¡ect on the Ca2 a⁄nity of the EGF
module in human fIX as in bovine fX. A feature speci¢c to
factors VII, IX and X and protein C is the presence of a Gln
residue N-terminal to the ¢rst Cys in the EGF module (posi-
tion 50 in human fIX), where most other EGF modules have
a Glu residue. Moreover, the fourth EGF module in protein
S, which binds Ca2 with very high a⁄nity, has a Glu residue
instead of the Val found at position 46 in fIX. To investigate
whether we could signi¢cantly increase the Ca2 a⁄nity of the
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EGF module, as a preparatory step for subsequent studies of
the e¡ect of such a mutation on the biological activity of fIX,
particularly its e¡ect on membrane and cofactor interactions,
we expressed the Gla*-EGF fragment (the asterisk denoting
Glu instead of Gla) from fIX with a Gln50Glu or Val46Glu
mutation and measured the calcium a⁄nity of the site in the
EGF module.
2. Materials and methods
2.1. Materials
AmpliTac polymerase was from Perkin Elmer. Restriction enzymes
were from Boehringer Mannheim. Autographa californica nuclear
polyhedrosis virus (AcMNPV) DNA and lipofectin were from In-
vitrogen. Phenylmethylsulfonyl £uoride (PMSF), L-1-tosylamide-2-
phenylethyl chloromethyl ketone (TPCK) treated trypsin, neutral
red, leupeptin and luminol were from Sigma. Diisopropyl £uorophos-
phate (DFP) and citraconic anhydride were from Fluka. TC-100
and SF 900 cell medium were from Gibco. Gelatin-Sepharose and
Sepharose S-100 were from Pharmacia Biotech. Molecular weight
standards and Chelex 100 resin were from Bio-Rad. Goat anti-mouse
antibodies labeled with horseradish peroxidase were from Dako.
The monoclonal antibody AW binds the N-terminal EGF module
of hfIX, is conformation speci¢c and has no a⁄nity for the reduced
EGF module (unpublished results). The antibody was a kind gift
from Dr. A. Wallmark, Department of Medicine, University Hospital,
Malmoº, Sweden.
2.2. Construction of vectors for expression of gelatin binding fIX
fragments
Ampli¢cation of hfIX cDNA sequences was accomplished with
standard PCR techniques. The following primer was used to create
the sense for all the fragments, starting at N-18, and to create a larger
primer for the mutations: 5P-GGCCATCCCCGTGGACAGTTT-
TTCTTGATCATGAAAAC. For all fragments, the C85 antisense is
5P-GGCCACGGGGATGGATCTAATTCACAGTTCTTTCCTTC.
The mutation V46E was made in two steps with the following anti-
sense primers: ¢rst 5P-ACACTGATCTCCATCATCATACTGCTTC-
CAAAA, and then 5P-TCACACTGATCTCCATCCTCATACTG-
CTTCCAAAA. For mutation Q50E, the antisense primer was 5P-
GATTGGACTCACACTCATCTCCATCAACAT. The bold letters
represent mutated nucleotides. Underlined sequences represent nu-
cleotides added to create a BstXI site. The ampli¢ed DNA was ligated
into the BstXI-cleaved expression vector GE-1/pGEM4, transformed
into the Escherichia coli strain DH5K and subcloned into the transfer
vector pAcYM1 as previously described [15].
The baculovirus transfer vectors were cotransfected with AcMNPV
DNA into Spodoptera frugiperda (Sf21) cells with lipofectin. Recombi-
nant viruses were plaque puri¢ed. For protein expression, Sf9 cells
were used as previously described [16]. After infection with the re-
combinant viruses, leupeptin was added and the cells were incubated
for 3 days at +27‡C in serum-free SF900 II medium. PMSF and DFP
were added to a ¢nal concentration of 2 mM. The proteins were ex-
pressed as fusion proteins with ¢bronectin, and after centrifugation at
10 000 rpm for 30 min the supernatant was loaded onto a ¢bronectin
binding gelatin-Sepharose 4B column, equilibrated in 20 mM Tris-
HCl, 150 mM NaCl, pH 7.4 (TBS). After washing with 1.0 M
NaCl in 20 mM Tris-HCl, pH 7.4, elution was carried out with 3.0
M guanidine-HCl, 20 mM Tris-HCl, pH 7.4. The fusion proteins were
dialyzed against TBS and stored at 370‡C. To prevent cleavage at
lysine residues, the proteins were citraconylated as described previ-
ously, and then digested with 0.05% (by weight) trypsin in 5 mM
CaCl2 for 15 min in 37‡C [15]. The reaction was terminated by addi-
tion of DFP to a ¢nal concentration of 5 mM. The lysine blocking
groups were removed by lowering the pH to 3.0 with glacial acetic
acid, and subsequent incubation overnight at +8‡C. pH was then
adjusted to 7.4 with NaOH before a second chromatography on the
gelatin-Sepharose column to remove free ¢bronectin and uncleaved
fusion protein. The digested protein was concentrated in a Filtron
Omegacell (cut o¡ 5 kDa) and gel ¢ltered on a Sepharose-100 column
loaded with 50 mM NH4HCO3. Before entering the Sepharose col-
umn, the bu¡er was made Ca2-free by passage through a Chelex 100
column.
2.3. Amino acid composition and sequence analysis
Amino acid compositions were determined after 24 h hydrolysis as
previously described [15]. Absorbance coe⁄cients (A1%1cm at 280 nm)
were determined by quantitative amino acid analysis of a solution
with known absorbance, and were found to be 20.2 for the non-mu-
tated recombinant fragment, 21.4 for the V46E fragment and 23.6 for
the Q50E fragment. The molecular weight used was 12 552 Da. N-
terminal sequences were determined on an Applied Biosystems 475 A
Pulsed Liquid Phase Sequencer.
2.4. SDS-PAGE and immunoblotting analysis
SDS-PAGE was performed according to Laemmli [17]. For immu-
noblotting, the proteins were transferred to an Immobilon transfer
membrane and detected by chemiluminescence as described [18], using
the monoclonal antibody AW that recognizes the ¢rst EGF module of
human fIX.
2.5. Solid phase immunoradiometric assay
To determine whether the recombinant protein fragments were
folded to their native conformations, a solid phase immunoradiomet-
ric assay was used. Microtiter plates were coated overnight at +4‡C
with the monoclonal antibody AW. The antibody, 50 Wl (10 Wg/ml),
was in sodium carbonate bu¡er, pH 9.6. The plates were washed ¢ve
times with washing bu¡er (50 mM Tris-HCl, 150 mM NaCl, 2 mM
CaCl2, pH 7.4), incubated at room temperature for 15 min with
blocking bu¡er (washing bu¡er with 1% BSA) and then washed again.
Increasing amounts of the recombinant proteins (after proteolytic re-
moval of the ¢bronectin part and puri¢cation, see above) or puri¢ed
hfIX were mixed with [125I]hfIX in blocking bu¡er and incubated at
room temperature for 3 h. The plates were washed and the bound
radioactivity measured.
2.6. Intrinsic protein £uorescence measurements
Intrinsic protein £uorescence was measured at 25‡C in an SLM
4800S spectro£uorometer (SLM Instruments, Rochester, NY) at a
protein concentration of 2 WM in 50 mM Tris, 0.1 M NaCl, pH
7.4. The excitation wavelength was 280 nm. Emission spectra were
recorded between 300 and 400 nm with excitation and emission band-
widths of 2 and 8 nm, respectively. Titrations with Ca2 were moni-
tored at an emission wavelength of 350 nm (corresponding to the
maximum £uorescence emission intensity of the fragments). The emis-
sion intensity was measured 2 min after each addition of 1^5 Wl 0.11
M CaCl2 by averaging 30 signal readings of 0.25 s each. Dissociation
constants and maximal £uorescence increases at calcium saturation
were determined by ¢tting the data to the equilibrium binding equa-
tion by non-linear regression [19]. For each fragment, the maximal
£uorescence increase and the Kd presented are means of 3^4 titrations
with the standard deviation noted in parentheses.
3. Results
A cDNA fragment consisting of the coding region for the
Gla* and N-terminal EGF-like modules was introduced into a
baculovirus-derived vector. The protein was expressed in Sf9
cells as a fusion protein with a deletion mutant of ¢bronectin
[20]. The ¢bronectin part of the recombinant protein allowed
rapid puri¢cation on gelatin-Sepharose. As cleavage with
thrombin, used in the original procedure, does not work ad-
jacent to the fIX EGF module, the gelatin binding part of
¢bronectin was removed by limited tryptic cleavage at Arg-
259 of ¢bronectin (removing residues 260^572) after reversible
protection of Lys residues by citraconylation. This precaution
was necessary in order to avoid cleavage at Lys-43 in the fIX
fragment. A ¢bronectin-derived tail of 26 amino acids, which
can be used to incorporate dansyl cadaverine and render the
protein £uorescent, remained attached to the C-terminus of
the EGF module (Fig. 1). The puri¢ed fragments were ana-
lyzed by SDS-PAGE (Fig. 2). Prior to tryptic cleavage the
fusion proteins yielded two bands as the ¢bronectin domain
was probably partially cleaved, either intracellularly or in the
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medium (Fig. 2). The EGF module of fIX contains two
unique potential glycosylation sites [21,22]. Aberrant glycosyl-
ation of these sites may account for the rather broad bands
seen on the gel. The amino acid compositions of the puri¢ed
fragments were in agreement with the composition deduced
from the known sequence of the fragments (not shown). N-
terminal sequence analysis of the cleaved and isolated frag-
ments showed the fragments to be more than 90% homoge-
neous (Table 1). There was no evidence of intrinsic cleavage in
the fragments. The fragments were made in insect cells, which
do not have the vitamin K-dependent carboxylase that con-
verts certain Glu residues to Gla [23]. However, decarboxyla-
tion of a bovine fIX fragment that contains the Gla and the
N-terminal EGF module does not a¡ect the Ca2 binding to
the N-terminal EGF module [24]. The L-hydroxyaspartic acid
content was 0.08^0.15 mol/mol of protein, as compared with
approximately 0.3 found in plasma-derived fIX [25].
Western blot experiments, using a conformation-dependent
antibody recognizing an epitope in the ¢rst EGF module of
hfIX, indicated the non-reduced recombinant protein to be
folded to a native conformation (not shown). The antibody
did not bind the reduced EGF module. As the cleaved re-
combinant proteins bound very poorly to the Immobilon
membrane, the fold of the Gla*EGF modules was probed in
a solid phase immunoradiometric assay (Fig. 3). The mutant
recombinant protein fragments and plasma-derived hfIX com-
peted equally well with [125I]hfIX for binding to the mono-
clonal antibody, suggesting that the EGF module was folded
to a native conformation.
The calcium binding properties of the recombinant fIX
fragments were characterized by £uorescence spectroscopy
(Fig. 4). In a fragment from bovine fIX including the Gla
module and the N- and C-terminal EGF modules, there is a
10% increase in £uorescence emission intensity at low calcium
concentrations, due to high a⁄nity Gla-independent binding
to the N-terminal EGF module [24]. This is followed by a
quenching of approximately 50% at higher calcium concen-
trations, caused by binding of calcium to sites with lower
a⁄nity in the Gla module. Somewhat smaller, although highly
reproducible, £uorescence enhancements than that noted for
the bovine fragment were also observed at micromolar calci-
um concentrations with the recombinant human fragments.
However, the quenching at higher concentrations was absent,
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Fig. 1. Schematic model of the recombinant fragment 1^85 of hfIX, including the N-terminal EGF module with the Ca2 ligands in gray. The
mutated residues are denoted by numbers 46 and 50. At the C-terminal end the sequence of the ¢bronectin part linked to the recombinant
fragment is shown.
Fig. 2. SDS-PAGE of recombinant fusion proteins and isolated
fragments. The sample load of each protein was 20 Wg, and the gel
was stained with Coomassie brilliant blue. Fus. prot. = fusion pro-
tein; Dig. prot. = digested protein; Non-mut = non-mutated.
Table 1
N-terminal amino acid sequence analysis of puri¢ed fragment hfIX
1^85
Non-mutated 46E 50E
Y 133 Y 87 Y 50
N 110 N 80 N 41
S 60 S 32 S 22
G 98 G 66 G 34
K 64 K 14 K 30











The numbers indicate the amount (in pmol) recovered in each cycle.
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as the recombinant fragments lack Gla residues. Quantitative
evaluation of titrations monitored by the £uorescence increase
gave a dissociation constant of 160 ( þ 40) WM for the wild
type fragment, consisting of residues 1^85 of human fIX. The
two mutant fragments, V46E and Q50E, showed a negligible
increase in Ca2 a⁄nity, the dissociation constants being
90 þ 40 WM and 90 þ 60 WM, respectively. The experimental
error is quite large, due to the small change in £uorescence,
but the increase in £uorescence is clearly reproducible. The
maximum fractional increase in £uorescence intensity at cal-
cium saturation was larger for the Q50E fragment
(0.027 þ 0.01) than for the wild type (0.016 þ 0.009) and
V46E fragments (0.016 þ 0.006), though the reason for this
is not known.
4. Discussion
The ¢rst EGF module of human fIX linked to the uncar-
boxylated Gla module has now been expressed in insect cells.
The conformation of the EGF module was native as judged
by a solid phase immunoradiometric assay using a conforma-
tion-speci¢c antibody. However, this experiment does not
prove that the uncarboxylated Gla module is folded to a na-
tive conformation. The three-dimensional structure of an un-
carboxylated Gla module has not yet been determined, but is
assumed to be similar to the structure of the carboxylated Gla
module from factor X in the absence of calcium, as deter-
mined by 2D NMR spectroscopy [6]. The recombinant pro-
teins were secreted from the insect cells, and in this respect
behave like the uncarboxylated forms of Gla modules secreted
from human and bovine hepatocytes, suggesting that the pro-
teins had attained a native conformation [26].
The ¢rst EGF module in human fIX contains a single cal-
cium binding site with a dissociation constant of 1.8 mM at
physiological ionic strength and 200^300 WM at low salt
[8,27,28]. In bovine factor IX it has been shown that a frag-
ment consisting of the decarboxylated Gla and the two EGF
modules contains a calcium binding site in the N-terminal
EGF-module with a dissociation constant of around 60 WM
at physiological ionic strength [24]. The corresponding EGF
module of bovine fX binds calcium with a dissociation con-
stant of W2.2 mM at physiological salt. However, when
linked to the Gla module the calcium a⁄nity increases to
120 WM at physiological salt, i.e. approximately 20-fold [11].
The site is thus essentially saturated at physiological free cal-
cium ion concentrations in extracellular £uids such as blood
plasma. The calcium a⁄nity of the corresponding sites in
factor VII and protein C, which have the same domain struc-
ture as factors IX and X, appears to be similar to those of the
EGF modules in these proteins [28]. We have now shown that
the dissociation constant for calcium in the ¢rst EGF module
of hfIX, when attached to the Gla* module, is around 160 WM
at physiological ionic strength, an approximately 10-fold in-
crease relative to the free EGF module. Human fIX thus
appears to behave as bovine fX in this respect.
The physiological signi¢cance of this calcium binding site is
illustrated by the fact that numerous mutations that a¡ect the
calcium ligands in the EGF module of factor IX result in the
biosynthesis of a protein with low biological activity (1^10%),
and causing a hemorrhagic disorder (hemophilia B) [7]. It has
been shown that, in the absence of calcium, both the Gla
module and the EGF module in fX are folded to characteristic
structures [5]. However, the two modules are very mobile
relative to each other. This mobility is lost when a calcium
ion is bound to the site in the EGF module; the calcium ion
locks the hinge between the two modules. The low biological
activity of fIX mutants which a¡ect the calcium ligands in the
EGF module is thus presumably due to an increased mobility
between the Gla and EGF modules that is incompatible with
biological activity. Recently it was proposed that the calcium
binding site in the N-terminal EGF module of factor VII is
important to orient the Gla relative to the N-terminal EGF
module in such a manner that interaction with tissue factor is
facilitated [29]. It thus appears as if the role of calcium bind-
ing to EGF modules is to induce an intermodule orientation
that is compatible with biological activity.
The characteristic sequence, immediately N-terminal of the
¢rst Cys residue, in calcium binding EGF modules that occur
in tandem in, for instance, protein S, ¢brillin, the Notch pro-
tein and the TGF-L binding protein, is Asp-Ile/Val-Asp-Glu
whereas factors VII, IX, and X and protein C all have the
sequence Asp-Gly-Asp-Gln in the corresponding position [18].
The isolated EGF modules from the coagulation factors bind
calcium with approximately the same a⁄nity as the isolated
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Fig. 4. Ca2 titration, monitored by intrinsic protein £uorescence,
of the recombinant digested fragments. Examples of titrations for
the (a) non-mutated, (O) V46E and (7) Q50E fragments. F and
F0 are the emission intensities in the presence and absence of Ca2,
respectively.
Fig. 3. Solid phase immunoradiometric assay of recombinant pro-
teins and native hfIX. The competitors were (a) hfIX, (O) non-mu-
tated, (b) V46E and (R) Q50E.
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EGF modules from protein S and ¢brillin. However, when
two or more EGF modules are linked together, the calcium
a⁄nity is increased [30,31]. In protein S, in which the N-ter-
minal sequence of the last EGF module has the sequence Glu-
Asp-Ile-Asp-Glu, the calcium a⁄nity of this site is very high,
i.e. nanomolar at physiological ionic strength. Handford and
colleagues found the Q50E mutation in a synthetic fIX EGF
module to increase the calcium a⁄nity 3.6 times [8]. Based on
the rationale that there might be a more drastic increase in the
calcium a⁄nity of the EGF module site if it was linked to the
Gla module, we expressed two Gla*-EGF modules with mu-
tations V46E and Q50E, that might increase the calcium af-
¢nity of the site. Both mutations appeared to have at most a
slightly increased calcium a⁄nity (Kd around 90 WM for
both), as compared with the wild type fragment. Q50 is a
Ca2 ligand, but it is interesting to note that V46 when mu-
tated to E also seems to imply an increase in Ca2 a⁄nity,
even though it is not considered to be a direct ligand for Ca2
binding [13]. However, similar e¡ects of changing the charge
around a calcium binding site have been observed before [32].
In conclusion, we have found that the ¢rst EGF module of
hfIX binds Ca2 with a Kd of around 160 WM when linked to
the Gla* domain, an approximately 10-fold increase in a⁄nity
as compared with the free EGF module. We have also dem-
onstrated the two mutations V46E and Q50E each to result in
a negligible increase in calcium a⁄nity.
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